DL
SPRY icon

Daniel Loeb’s ARS Pharmaceuticals SPRY Stock Holding History

Daniel Loeb’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.01M Hold
1,000,000
– – 0.17% 31
2026
Q1 		$8.03M Buy
1,000,000
+443,763
+80% +$4.25M 0.39% 28
2025
Q4 		$6.48M Buy
+556,237
New +$5.41M 0.09% 37

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Daniel Loeb's SPRY Position: Q2 2026 in Review

Daniel Loeb held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 1,000,000 shares worth $8.01M. The position accounts for 0.17% of the portfolio, ranked #31.

Daniel Loeb first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.03M in Q1 2026. 205 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Daniel Loeb held 1,000,000 shares of ARS Pharmaceuticals worth $8.01M as of Q2 2026.
  • Daniel Loeb left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up 0.17% of Daniel Loeb's portfolio in Q2 2026, its #31 holding.
  • Daniel Loeb first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Daniel Loeb's ARS Pharmaceuticals position peaked at $8.03M in Q1 2026.
  • 205 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Third Point's 13F filing for Q2 2026, filed 14 Aug 2026.